Thalidomide and sensory neurotoxicity: a neurophysiological study

Zara, Gabriella; Ermani, Mario; Rondinone, R; Arienti, Silvia; Doria, Andrea

doi:10.1136/jnnp.2008.147892

Cited by 37 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are essential for the Nowadays they are still being used as the gold standard in some ongoing clinical trials. They can be helpful in deciding when to stop treatment [18]. They allow quantifi cation of the damage in the nerve and can also characterise the specifi c site of the lesion, i.e., differentiating a demyelinating neuropathy from an axonal neuropathy.…”

Section: Nerve Function Studiesmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies

et al. 2010

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer treatment and its incidence is growing. It significantly affects quality of life and is a dose-limiting factor that interferes with treatment. Its diagnosis can be established in clinical terms but some complementary tests can help when the diagnosis is difficult. There is still no proven method to prevent it that has become a standard of care in spite of the huge amount of investigation carried out in recent years. There are promising strategies that could help reduce the burden of this complication. This review will suggest an approach to the diagnosis of these disorders and provide an update on new therapies.

show abstract

Section: Nerve Function Studiesmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Neuropathy remains one of the common adverse events of thalidomide treatment, representing the most common reason for thalidomide dose reduction and cessation in patients with multiple myeloma . The overall incidence of neuropathy ranges up to 83% of patients, presenting as a sensory neuropathy with prominent symptoms of paresthesia in the hands and feet, numbness, and mild motor involvement including muscle cramps and weakness . Thalidomide‐induced neuropathy involves both small‐ and large‐fiber sensory dysfunction and is most prominent in the distal lower limbs …”

Section: Chemotherapies Associated With Cipnmentioning

confidence: 99%

“…Trials have identified that neuropathic symptoms typically improved within 3 to 4 months after the cessation of thalidomide treatment in 90% of patients . However, studies in patients with other disorders who were treated with thalidomide for more than 2 years have suggested limited and slow reversibility of neuropathy …”

Section: Chemotherapies Associated With Cipnmentioning

confidence: 99%

Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

Park

Goldstein

Krishnan

et al. 2013

CA A Cancer J Clinicians

622

590

View full text Add to dashboard Cite

With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies.

show abstract

“…Generally, in these studies, complete or marked regression of disease is seen in 80 --90% [49][50][51][52]. However, use has been limited due to the risk of peripheral neuropathy [53]. This potentially irreversible side effect is not uncommon, occurring in up to 50% of patients.…”

Section: Thalidomidementioning

confidence: 98%